²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Conditions:   Plasma Cell Myeloma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Total-Body Irradiation Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials